09:02 AM EDT, 07/18/2024 (MT Newswires) -- Exscientia ( EXAI ) said on Thursday it is acquiring GT Apeiron's stake in its cancer drug program, gaining full control of GTAEXS617 and associated intellectual property.

The company said the recruitment for the trial, designed to test the safety and efficacy of GTAEXS617 in treating advanced forms of cancer, is progressing smoothly, with monotherapy dose escalation data anticipated by H2 2024.

In late 2024 or early 2025, the study will transition to combination dose escalation, starting with HR+/HER2- breast cancer patients who have advanced CDK4/6 inhibitors.

Exscientia ( EXAI ) will pay GT Apeiron $20 million, half in cash and half in equity, and take on all existing development costs, in addition to paying single digit royalties if Exscientia ( EXAI ) or a third party commercializes GTAEXS617.

The company said the acquisition will secure its financial runway through 2027.

Price: 5.50, Change: +0.10, Percent Change: +1.84